Study Title: Pulmonary Arterial Hypertension (PAH) in scleroderma patents Quality Enhancement Research Initiative (QuERI) Extension Program. (Identifier: NCT01389206)
Study Purpose: This program intends to improve the management of pulmonary arterial hypertension (PAH) patients through an evidence-based approach aimed at achieving optimal World Health Organization (WHO) functional class (FC): 1. Improving FC III & IV patients to FC II, 2. Improving FC II patients to FC I, and 3. Maintaining FC II & FC I patients.
Principal Investigator: Bashar Kahaleh, M.D.
Study Coordinator: Stephanie J. Smiddy, RN, for more information, please contact 419.383.6921.